Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Healthequity (HQY) EBITDA Margin (2016 - 2026)

Healthequity has reported EBITDA Margin over the past 14 years, most recently at 21.24% for Q1 2026.

  • Quarterly results put EBITDA Margin at 21.24% for Q1 2026, up 1279.0% from a year ago — trailing twelve months through Jan 2026 was 22.33% (up 1427.0% YoY), and the annual figure for FY2026 was 24.55%, up 1649.0%.
  • EBITDA Margin for Q1 2026 was 21.24% at Healthequity, down from 24.43% in the prior quarter.
  • Over the last five years, EBITDA Margin for HQY hit a ceiling of 27.5% in Q3 2025 and a floor of 16.14% in Q1 2022.
  • Median EBITDA Margin over the past 5 years was 5.89% (2023), compared with a mean of 6.76%.
  • Biggest five-year swings in EBITDA Margin: plummeted -1900bps in 2022 and later soared 2253bps in 2025.
  • Healthequity's EBITDA Margin stood at 0.76% in 2022, then soared by 875bps to 5.89% in 2023, then plummeted by -68bps to 1.9% in 2024, then surged by 1187bps to 24.43% in 2025, then decreased by -13bps to 21.24% in 2026.
  • The last three reported values for EBITDA Margin were 21.24% (Q1 2026), 24.43% (Q4 2025), and 27.5% (Q3 2025) per Business Quant data.